series-b
Stage
2
Investors
About
AlgoTherapeutix is a clinical-stage biotechnology company focused on developing non-opioid therapies for peripheral neuropathic pain. Its lead candidate, ATX01, is a topical formulation of amitriptyline designed to inhibit pain signaling by targeting peripheral sensory nerve fibers, specifically for chemotherapy-induced peripheral neuropathy and erythromelalgia.
Explore ALGOTHERAPEUTIX's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.